Figure 5

Cognitive function in AD patients receiving galantamine 24 mg/day for 12 months or placebo for 6 months followed by galantamine 24 mg/day for 6 months [51]. Although patients who took galantamine 24 mg/day for 12 months were able to maintain cognitive function at baseline levels, patients who were on placebo for the first 6 months and then switched to galantamine could not achieve this level of functioning, indicating that early treatment provides the greatest benefit. (From Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology. 2000;54:2261-8.)